Приказ основних података о документу
Liquid chromatographic-mass spectrometric method for the determination of fluoxetine and norfluoxetine in human plasma: Application to clinical study
dc.creator | Đorđević, S | |
dc.creator | Kovacević, I | |
dc.creator | Miljković, Branislava | |
dc.creator | Vuksanović, J | |
dc.creator | Pokrajac, Milena | |
dc.date.accessioned | 2019-09-02T11:02:14Z | |
dc.date.available | 2019-09-02T11:02:14Z | |
dc.date.issued | 2005 | |
dc.identifier.issn | 0014-827X | |
dc.identifier.uri | https://farfar.pharmacy.bg.ac.rs/handle/123456789/641 | |
dc.description.abstract | A selective, sensitive, simple, and rapid method for the simultaneous determination of fluoxetine (FL) and norfluoxetine (nor-FL) was developed and validated, and further applied to analyze plasma samples obtained from FL-treated patients with Parkinson disease (n:=:18). After one step liquid-liquid extraction with ethyl acetate, plasma samples were chromatographed on a C8 column. The mobile phase was acetate buffer and acetonitrile (40:60 v/v). Determination of FL and nor-FL was performed with MS detection in selective ion monitoring (SIM) mode, so the other components did not interfere with this assay. FL, nor-FL and flumazenil as internal standard were eluted in 6:min. Recoveries ranged from 89.7 to 96.6% and from 80.2 to 85.3% for FL and nor-FL, respectively. The limit of quantitation under described conditions was 2,5 μg/l for FL and 10 μg/l for nor-FL. The method was found to be reproducible with coefficient of variation less than 9%. The parameters of the method were found to be acceptable to enable its routine use for clinical studies. The method was employed to analyze the Parkinsonian patients' plasma samples. A great deviation in plasma concentrations of FL and nor-FL found among 18 studied patients indicates high pharmacokinetic variability of the drug. Obtained results also indicate absence of the influence of Parkinson disease on the drug disposition. | en |
dc.publisher | Elsevier Masson SAS | |
dc.rights | restrictedAccess | |
dc.source | Farmaco | |
dc.subject | Fluoxetine | en |
dc.subject | High performance liquid chromatography | en |
dc.subject | Mass spectrometry | en |
dc.subject | Norfluoxetine | en |
dc.subject | Pharmacokinetics | en |
dc.title | Liquid chromatographic-mass spectrometric method for the determination of fluoxetine and norfluoxetine in human plasma: Application to clinical study | en |
dc.type | article | |
dc.rights.license | ARR | |
dcterms.abstract | Ђорђевић, С; Вуксановић, Ј; Ковацевић, И; Миљковић, Бранислава; Покрајац, Милена; | |
dc.citation.volume | 60 | |
dc.citation.issue | 4 | |
dc.citation.spage | 345 | |
dc.citation.epage | 349 | |
dc.citation.other | 60(4): 345-349 | |
dc.identifier.doi | 10.1016/j.farmac.2005.01.002 | |
dc.identifier.scopus | 2-s2.0-17444431165 | |
dc.type.version | publishedVersion |